Lexeo Therapeutics (LXEO) Share-based Compensation (2022 - 2026)

Lexeo Therapeutics has disclosed Share-based Compensation across 5 years of filings, most recently posting $2.8 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.8 million, down 25.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (down 19.15% YoY), and the FY2025 annual result was $12.1 million, down 2.74% from the prior year.
• Share-based Compensation came in at $2.8 million for Q1 2026 at Lexeo Therapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q3 2024 to a low of $397000.0 in Q1 2023.
• The 5-year median for Share-based Compensation is $2.7 million (2025), against an average of $2.1 million.
• Across the five-year window, Share-based Compensation surged 487.15% in 2024 and slumped 30.05% in 2025, its largest moves.
• Lexeo Therapeutics' Share-based Compensation stood at $521000.0 in 2022, then soared by 54.32% to $804000.0 in 2023, then jumped by 336.19% to $3.5 million in 2024, then retreated by 22.64% to $2.7 million in 2025, then grew by 1.55% to $2.8 million in 2026.
• The last three Share-based Compensation figures came in at $2.8 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.